Integrating in vitro and in silico approaches for exploring antidiabetic potential of dimethyl and thiomethyl indolinone derivatives.

Diabetes mellitus (DM) is a metabolic disorder caused by insulin deficiency. It is a rapidly growing problem with immense social, economic and health related problems. The market available drugs for the management of DM possess several limitations and therefore the discovery of more effective agents...

Full description

Saved in:
Bibliographic Details
Main Authors: Kashif Ali, Ahmed A Elhenawy, Waqas Alam, Khalaf F Alsharif, Khalid J Alzahrani, Haroon Khan, Long Chiau Ming, Rahul G Ingle
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0319987
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849328790003515392
author Kashif Ali
Ahmed A Elhenawy
Waqas Alam
Khalaf F Alsharif
Khalid J Alzahrani
Haroon Khan
Long Chiau Ming
Rahul G Ingle
author_facet Kashif Ali
Ahmed A Elhenawy
Waqas Alam
Khalaf F Alsharif
Khalid J Alzahrani
Haroon Khan
Long Chiau Ming
Rahul G Ingle
author_sort Kashif Ali
collection DOAJ
description Diabetes mellitus (DM) is a metabolic disorder caused by insulin deficiency. It is a rapidly growing problem with immense social, economic and health related problems. The market available drugs for the management of DM possess several limitations and therefore the discovery of more effective agents is the need of time. The current study was designed to evaluate two oxindole derivatives: (E)-3-(2,4-Dimethylbenzylidene)-6-chloroindolin-2-one (compound 1), and (E)-3-(4-(Methylthio) benzylidene)-6-chloroindolin-2-one (compound 2) against α-amylase, protein glycation, and DPP-IV. In case of in vitro antidiabetic activities, compound 1 demonstrated significant inhibition at various concentrations with IC50 value of 32.917 µg/mL against α-amylase, 210.592 µg/mL against protein glycation and 31.28 µg/mL against DPP-IV. Similarly, when tested at various concentrations, compound 2 illustrated marked inhibition with IC50 value of 42.691 µg/mL on α- amylase, 341.551 µg/mL on protein glycation and 47.192 µg/mL against DPP-IV. Molecular docking studies identified the binding patterns of oxindoles in the active site of targeted protein and enzymes. Moreover, the docking analysis also showed the potent interaction of test compounds with the target sites against α-amylase, protein glycation and DPP-IV. In conclusion, both the compounds are significant inhibitors of α-amylase, protein glycation and DPP-IV in vitro assays with the support of molecular dynamic studies and therefore are potential candidates for further studies.
format Article
id doaj-art-40c88e98155c496e87e6ca27a07efeb5
institution Kabale University
issn 1932-6203
language English
publishDate 2025-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-40c88e98155c496e87e6ca27a07efeb52025-08-20T03:47:28ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01205e031998710.1371/journal.pone.0319987Integrating in vitro and in silico approaches for exploring antidiabetic potential of dimethyl and thiomethyl indolinone derivatives.Kashif AliAhmed A ElhenawyWaqas AlamKhalaf F AlsharifKhalid J AlzahraniHaroon KhanLong Chiau MingRahul G IngleDiabetes mellitus (DM) is a metabolic disorder caused by insulin deficiency. It is a rapidly growing problem with immense social, economic and health related problems. The market available drugs for the management of DM possess several limitations and therefore the discovery of more effective agents is the need of time. The current study was designed to evaluate two oxindole derivatives: (E)-3-(2,4-Dimethylbenzylidene)-6-chloroindolin-2-one (compound 1), and (E)-3-(4-(Methylthio) benzylidene)-6-chloroindolin-2-one (compound 2) against α-amylase, protein glycation, and DPP-IV. In case of in vitro antidiabetic activities, compound 1 demonstrated significant inhibition at various concentrations with IC50 value of 32.917 µg/mL against α-amylase, 210.592 µg/mL against protein glycation and 31.28 µg/mL against DPP-IV. Similarly, when tested at various concentrations, compound 2 illustrated marked inhibition with IC50 value of 42.691 µg/mL on α- amylase, 341.551 µg/mL on protein glycation and 47.192 µg/mL against DPP-IV. Molecular docking studies identified the binding patterns of oxindoles in the active site of targeted protein and enzymes. Moreover, the docking analysis also showed the potent interaction of test compounds with the target sites against α-amylase, protein glycation and DPP-IV. In conclusion, both the compounds are significant inhibitors of α-amylase, protein glycation and DPP-IV in vitro assays with the support of molecular dynamic studies and therefore are potential candidates for further studies.https://doi.org/10.1371/journal.pone.0319987
spellingShingle Kashif Ali
Ahmed A Elhenawy
Waqas Alam
Khalaf F Alsharif
Khalid J Alzahrani
Haroon Khan
Long Chiau Ming
Rahul G Ingle
Integrating in vitro and in silico approaches for exploring antidiabetic potential of dimethyl and thiomethyl indolinone derivatives.
PLoS ONE
title Integrating in vitro and in silico approaches for exploring antidiabetic potential of dimethyl and thiomethyl indolinone derivatives.
title_full Integrating in vitro and in silico approaches for exploring antidiabetic potential of dimethyl and thiomethyl indolinone derivatives.
title_fullStr Integrating in vitro and in silico approaches for exploring antidiabetic potential of dimethyl and thiomethyl indolinone derivatives.
title_full_unstemmed Integrating in vitro and in silico approaches for exploring antidiabetic potential of dimethyl and thiomethyl indolinone derivatives.
title_short Integrating in vitro and in silico approaches for exploring antidiabetic potential of dimethyl and thiomethyl indolinone derivatives.
title_sort integrating in vitro and in silico approaches for exploring antidiabetic potential of dimethyl and thiomethyl indolinone derivatives
url https://doi.org/10.1371/journal.pone.0319987
work_keys_str_mv AT kashifali integratinginvitroandinsilicoapproachesforexploringantidiabeticpotentialofdimethylandthiomethylindolinonederivatives
AT ahmedaelhenawy integratinginvitroandinsilicoapproachesforexploringantidiabeticpotentialofdimethylandthiomethylindolinonederivatives
AT waqasalam integratinginvitroandinsilicoapproachesforexploringantidiabeticpotentialofdimethylandthiomethylindolinonederivatives
AT khalaffalsharif integratinginvitroandinsilicoapproachesforexploringantidiabeticpotentialofdimethylandthiomethylindolinonederivatives
AT khalidjalzahrani integratinginvitroandinsilicoapproachesforexploringantidiabeticpotentialofdimethylandthiomethylindolinonederivatives
AT haroonkhan integratinginvitroandinsilicoapproachesforexploringantidiabeticpotentialofdimethylandthiomethylindolinonederivatives
AT longchiauming integratinginvitroandinsilicoapproachesforexploringantidiabeticpotentialofdimethylandthiomethylindolinonederivatives
AT rahulgingle integratinginvitroandinsilicoapproachesforexploringantidiabeticpotentialofdimethylandthiomethylindolinonederivatives